Centrosome hyperamplification and chromosomal instability in bladder cancer

European Urology

Volumn 43, Issue 5, 2003, Pages 505-515

  Kawamura, K ^a   Moriyama, M ^a   Shiba, N ^a   Ozaki, M ^a   Tanaka, T ^a   Nojima, T ^a   Fujikawa Yamamoto, K ^a   Ikeda, R ^a   Suzuki, K ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

Bladder cancer; Centrosome hyperamplification; Chromosomal instability; FISH; Pericentrin

Indexed keywords

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CELL DIVISION; CENTROSOME; CHROMOSOME 17; CHROMOSOME 3; CHROMOSOME 7; CHROMOSOME ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMETRY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENETIC STABILITY; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; REGULATORY MECHANISM; TRANSURETHRAL RESECTION;

EID: 0037629036     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(03)00056-3     Document Type: Article

References (37)

1. Brinkley BR. Microtubule organizing centers. Annu Rev Cell Biol 1985;1:145-72.
2. Andersen SS. Molecular characteristics of centrosome. Int Rev Cytol 1999;187:51-109.
3. Lange BM, Faragher AJ, March P, Gull K. Centriole duplication and maturation in animal cells. Curr Top Dev Biol 2000;49:235-49.
4. Boveri T. The origin of malignant tumors. Baltimore: Williams & Wilkins; 1929.
5. Fukasawa K, Choi T, Kuriyama R, Rulong S, Vande Woude GF. Abnormal centrosome amplification in the absence of p53. Science 1996;271:1744-7.
6. Fukasawa K, Wiener F, Vande Woude GF, Mai S. Genomic instability and apoptosis are frequent in p53 deficient mice. Oncogene 1997;15:1295-302.
7. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancer cancers. Nature 1997;386:623-7.
8. Zhao J, Richter J, Wagner U, Roth B, Schraml P, Zellweger TR, et al. Chromosomal imbalances in non invasive papillary bladder neoplasms (pTa). Cancer Res 1999;59:4658-61.
9. Mostofi F, Sobin L, Torloni H. Histological typing of urinary bladder tumors. Geneva: World Health Organization; 1973.
10. Sobin LH, Wittekind C. UICC TNM classification of malignant tumors, 6th ed. Revised. New York: Wiley; 2002. p. 199-202.
11. Doxsey SJ, Stein P, Evance L, Calarco P, Kirschner M. Pericentrin, a highly conserved protein of centrosomes involved in microtubule organization. Cell 1994;76:639-50.
12. Carroll PE, Okuda M, Horn FH, Biddinger P, Stambrook PJ, Gleich LL, et al. Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or Mdm2 overexpression. Oncogene 1999;18:1935-44.
13. Mussman JG, Horn HF, Carroll PE, Okuda M, Tarapore P, Donehower LA, et al. Synergistic induction of centrosome hyperamplification by loss of p53 and cyclin E overexpression. Oncogene 2000;19:1635-46.
14. Halling CH, King W, Sokolova IA, Meyer RG, Burkhardt HM, Halling AC, et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol 2000;164:1768-75.
15. Kawamura K, Ikeda R, Suzuki K. The relationships among DNA ploidy type determined by laser scanning cytometry: The overexpression of p53 protein and the numerical aberrations of chromosome 7 in bladder cancer. Acta Urol Japonica 2000;46:377-88.
16. Kawamura K, Tanaka T, Ikeda R, Fujikawa-Yamamoto K, Suzuki K. DNA ploidy analysis of urinary tract epithelial tumors by laser scanning cytometry. Anal Quant Cytol Histol 2000;22:26-30.
17. Kawamura K, Kobayashi Y, Tanaka T, Ikeda R, Fujikawa-Yamamoto K, Suzuki K. Intranuclear localization of proliferative cell nuclear antigen during the cell cycle in renal cell carcinoma. Anal Quant Cytol Histol 2000;22:26-30.
18. Lingle WL, Lutz WH, Ingle JN, Maihle NJ, Salisbury JL. Centrosome hypertrophy in human breast tumors: Implications for genomic stability and cell polarity. Cell Biol 1998;95:2950-5.
19. Lingle WL, Salisbury JL. Altered centrosome structure is associated with abnormal mitoses in human breast tumors. Am J Pathol 1999;155:1941-51.
20. Phihan GA, Purohit A, Wallace J, Knecht H, Woda B, Quesenberry P, et al. Centrosome defects and genetic instability in malignant tumors. Cancer Res 1998;58:3974-85.
21. Weber RG, Bridger JM, Benner A, Weisenberger D, Ehemann V, Reifenberger G, et al. Centrosome amplification as a possible mechanism for numerical chromosome aberrations in cerebral primitive neuroectodermal tumors with TP53 mutations. Cytogenet Cell Genet 1998;83:266-8.
22. Kuo KK, Sato N, Mizumoto K, Maehara N, Yonematsu H, Ker CG, et al. Centrosome abnormalities in human carcinomas of the gallbladder and intrahepatic and extrahepatic bile ducts. Hepatology 2000;31:59-64.
23. Lingle WL, Barret SL, Negron CV, D'Assoro AB, Boeneman KB, Liu W, et al. Centrosome amplification drives instability in breast tumor development. Proc Natl Acad Sci USA 2002;99:1978-83.
24. Pihan GA, Purohit A, Wallace J, Malhotra R, Liotta L, Doxsey SJ. Centrosome defects can account for cellular and genetic changes that characterize prostate cancer progression. Cancer Res 2001;61:2212-9.
25. Tarapore P, Fukasawa K. p53 mutation and mitotic infidelity. Cancer Invest 2000;18:148-55.
26. Harris CC, Hollstein M. Clinical implication of the p53 tumorsuppressor gene. N J Med 1993;329:1318-27.
27. Fujimoto K, Yamada Y, Okajima E, Kakizoe T, Sasaki H, Sugimura T, et al. Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res 1992;52:1393-8.
28. Sidransky D, Escenbach AV, Tsai YC, Jones P, Summerhayes I, Marshall F, et al. Identification of p53 gene mutation in bladder cancers and urine samples. Science 1991;252:706-9.
29. Xu X, Weaver Z, Linkle SP, Li C, Gotay J, Wang X-W, et al. Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoformdeficient cells. Mol Cell 1999;3:389-95.
30. Hollander MC, Sheikh MS, Bulavin DV, Lundgren K, AugeriHenmueller L, Shehee R, et al. Genomic instability in Gadd45adeficient mice. Nat Genet 1999;23:176-84.
31. Mainguene C, Choquenet C, Deplano C, Gavelli A, Clement N, Vanzo E, et al. DNA ploidy by image cytometry in urothelial carcinomas. Comparison of touch imprints and paraffin-embedded biopsies from 31 patients. Anal Quant Cytol Histol 1997;19:437-42.
32. Sao JL, Eatable Y, Marcela ID, Hajyan K, Jones PA, Shibata D. Bladder cancer genotype stability during clinical progression. Gene Chromosome Cancer 2000;29:26-32.
33. Yu DS, Chen HI, Chang SY. Chromosomal aberrations in transitional cell carcinoma: its correlation with tumor behavior. Urol Int 2002;69:129-35.
34. Pycha A, Mian C, Haitel A, Hofbauer J, Wiener H, Marberger M. Fluorescence in situ hybridization identifies more aggressive types of primarily noninvasive (stage pTa) bladder cancer. J Urol 1997;157:2116-9.
35. Sarosdy MF, Schellhammer P, Bokinsky G, Kahn P, Chao R, Yore L, et al. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 2002;168:1950-4.
36. Spruck III CH, Ohneseit PF, Gonzalez-Zulueta M, Esrig D, Miyao N, Tsai YC, et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994;54:784-8.
37. Tsai YC, Nichols PW, Hiti AL, Williams Z, Skinner DG, Jones PA. Allelic losses of chromosomes 9, 11, and 17 in human bladder cancer. Cancer Res 1990;50:44-7.